Most Read News

EBITDA margin for the quarter stood at 15.7%, slightly lower than the 16.5% margin recorded in the corresponding period of the previous fiscal year.

The company's net profit stood at ₹434.7 crore in Q4FY25, significantly higher compared to ₹140.3 crore recorded in the same quarter of the previous fiscal year.

The EBITDA of the company declined sharply to ₹21 crore, much lower than the ₹306.42 crore it clocked in the March quarter of the last financial year.

UltraTech Cement is the only stock that hits 52-week high in Sensex and Nifty

The company's top line, revenue from operations, declined 2.7% YoY at ₹778.8 crore in Q4 FY25, from ₹800.2 crore during the corresponding quarter of FY24.

Dr Lal PathLabs declared a fourth interim dividend of ₹6 per share for 2025, reflecting its strong cash generation and shareholder remittance focus.

EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortisation) during the quarter rose 32% to ₹4,820 crore.

In Q4FY25, net interest income (NII) came down 2% YoY at ₹1,563 crore, compared to ₹1,600 crore during the same period last year.

Indian shares ended steady in a volatile week that was marred by rising geopolitical tensions while the tarriff war showed signs of abating.

IIP edged up marginally in March 2025, although the picture of prior period revisions was relatively mixed